These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 36590752)
1. Prognostic Value of Lymphocyte-to-Monocyte Ratio (LMR) in Cancer Patients Undergoing Immune Checkpoint Inhibitors. Wan L; Wu C; Luo S; Xie X Dis Markers; 2022; 2022():3610038. PubMed ID: 36590752 [TBL] [Abstract][Full Text] [Related]
2. Prognostic value of inflammatory markers NLR, PLR, and LMR in gastric cancer patients treated with immune checkpoint inhibitors: a meta-analysis and systematic review. Tan S; Zheng Q; Zhang W; Zhou M; Xia C; Feng W Front Immunol; 2024; 15():1408700. PubMed ID: 39050856 [TBL] [Abstract][Full Text] [Related]
3. Prognostic value of lymphocyte-to-monocyte ratio in gastric cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Mei P; Feng W; Zhan Y; Guo X Front Immunol; 2023; 14():1321584. PubMed ID: 38090560 [TBL] [Abstract][Full Text] [Related]
4. The relationship between NLR/PLR/LMR levels and survival prognosis in patients with non-small cell lung carcinoma treated with immune checkpoint inhibitors. Liu N; Mao J; Tao P; Chi H; Jia W; Dong C Medicine (Baltimore); 2022 Jan; 101(3):e28617. PubMed ID: 35060536 [TBL] [Abstract][Full Text] [Related]
5. Effects of glucocorticoid use on survival of advanced non-small-cell lung cancer patients treated with immune checkpoint inhibitors. Li N; Zheng X; Gan J; Zhuo T; Li X; Yang C; Wu Y; Qin S Chin Med J (Engl); 2023 Nov; 136(21):2562-2572. PubMed ID: 37925595 [TBL] [Abstract][Full Text] [Related]
6. How to Choose a Survival Period? The Impact of Antibiotic Use on OS or PFS in NSCLC Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Chen H; Han KD; He ZJ; Huang YS Technol Cancer Res Treat; 2021; 20():15330338211033498. PubMed ID: 34323149 [TBL] [Abstract][Full Text] [Related]
7. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis. Zhang N; Jiang J; Tang S; Sun G Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712 [TBL] [Abstract][Full Text] [Related]
8. The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors. Zhou J; Huang G; Wong WC; Hu DH; Zhu JW; Li R; Zhou H Front Immunol; 2022; 13():968729. PubMed ID: 35967438 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: A meta-analysis. Shen K; Cui J; Wei Y; Chen X; Liu G; Gao X; Li W; Lu H; Zhan P; Lv T; Lin D J Thorac Dis; 2018 Dec; 10(12):6636-6652. PubMed ID: 30746209 [TBL] [Abstract][Full Text] [Related]
10. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer. Grangeon M; Tomasini P; Chaleat S; Jeanson A; Souquet-Bressand M; Khobta N; Bermudez J; Trigui Y; Greillier L; Blanchon M; Boucekine M; Mascaux C; Barlesi F Clin Lung Cancer; 2019 May; 20(3):201-207. PubMed ID: 30442524 [TBL] [Abstract][Full Text] [Related]
11. Patients with melanoma treated with immune checkpoint inhibitors who had non-thyroid endocrine and skin immune-related adverse events have better prognosis: A systematic review and meta-analysis. Sun Q; Sun H; Wu N; Hu Y; Zhang F; Cong X Front Oncol; 2022; 12():976224. PubMed ID: 36185176 [TBL] [Abstract][Full Text] [Related]
12. Association of Lymphocyte-to-Monocyte Ratio With Survival in Advanced Gastric Cancer Patients Treated With Immune Checkpoint Inhibitor. Chen Y; Zhang C; Peng Z; Qi C; Gong J; Zhang X; Li J; Shen L Front Oncol; 2021; 11():589022. PubMed ID: 34141607 [TBL] [Abstract][Full Text] [Related]
13. Impact of probiotics use on clinical outcomes of immune checkpoint inhibitors therapy in cancer patients. Wan L; Wu C; Wu Q; Luo S; Liu J; Xie X Cancer Med; 2023 Jan; 12(2):1841-1849. PubMed ID: 35770869 [TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of circulating monocytes and lymphocyte-to-monocyte ratio on previously untreated metastatic non-small cell lung cancer patients receiving platinum-based doublet. Lin GN; Peng JW; Xiao JJ; Liu DY; Xia ZJ Med Oncol; 2014 Jul; 31(7):70. PubMed ID: 24927957 [TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of Pretreatment Lymphocyte-to-Monocyte Ratio in Non-Small Cell Lung Cancer: A Meta-Analysis. Wang Y; Huang D; Xu WY; Wang YW; Che GW Oncol Res Treat; 2019; 42(10):523-531. PubMed ID: 31319409 [TBL] [Abstract][Full Text] [Related]
17. Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer. Sekine K; Kanda S; Goto Y; Horinouchi H; Fujiwara Y; Yamamoto N; Motoi N; Ohe Y Lung Cancer; 2018 Oct; 124():179-188. PubMed ID: 30268458 [TBL] [Abstract][Full Text] [Related]
18. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis. Ba H; Liu L; Peng Q; Chen J; Zhu YD BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004 [TBL] [Abstract][Full Text] [Related]
19. The impact of antibiotics on efficacy of immune checkpoint inhibitors in malignancies: A study based on 44 cohorts. Wu Q; Liu J; Wu S; Xie X Int Immunopharmacol; 2021 Mar; 92():107303. PubMed ID: 33465728 [TBL] [Abstract][Full Text] [Related]
20. Clinical Significance of Serum Biomarkers in Stage IV Non-Small-Cell Lung Cancer Treated with PD-1 Inhibitors: LIPI Score, NLR, dNLR, LMR, and PAB. Chen J; Wei S; Zhao T; Zhang X; Wang Y; Zhang X Dis Markers; 2022; 2022():7137357. PubMed ID: 35945957 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]